{"id":"NCT00368108","sponsor":"Eisai Inc.","briefTitle":"Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations","officialTitle":"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-08","primaryCompletion":"2008-01","completion":"2008-01","firstPosted":"2006-08-24","resultsPosted":"2013-02-05","lastUpdate":"2013-05-20"},"enrollment":752,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson's Disease"],"interventions":[{"type":"DRUG","name":"2 mg perampanel","otherNames":[]},{"type":"DRUG","name":"4 mg perampanel","otherNames":[]},{"type":"DRUG","name":"placebo comparator","otherNames":[]}],"arms":[{"label":"2 mg perampanel","type":"EXPERIMENTAL"},{"label":"4 mg perampanel","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a multi-center, randomized, double-blind, placebo-controlled, parallel-group study of E2007 in levodopa treated Parkinson's disease patients with motor fluctuations.","primaryOutcome":{"measure":"Mean Change From Baseline in Total Daily OFF Time (Hours) to Week 20 (Including Last Observation Carried Forward [LOCF] Data)","timeFrame":"Baseline and Week 20","effectByArm":[{"arm":"Placebo","deltaMin":-0.96,"sd":null},{"arm":"Perampanel 2mg","deltaMin":-0.93,"sd":null},{"arm":"Perampanel 4mg","deltaMin":-0.76,"sd":null}],"pValues":[]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":114,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":250},"commonTop":["Dyskinesia","Somnolence","Fall","ON and OFF phenomenon","Dizziness"]}}